Janux commences participant dosing in Phase I JANX011 trial

​Janux Therapeutics has dosed the first participant in a Phase I clinical trial of JANX011, a CD19-targeted bispecific candidate designed using its ARM platform.

The post Janux commences participant dosing in Phase I JANX011 trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Portal Diabetes’ insulin pump receives FDA breakthrough device designation 
J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC
VB Spine to acquire xvision Spine System from Augmedics
CStone secures FDA clearance to begin CS2009 Phase II trial
ExCellThera secures German NUB Status 1 listing for Zemcelpro

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us